

# Thomas Karagiannis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115814/publications.pdf>

Version: 2024-02-01

38  
papers

2,658  
citations

489802

18  
h-index

371746

37  
g-index

38  
all docs

38  
docs citations

38  
times ranked

3447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	2.2	19
2	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
3	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	2.2	17
4	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	2.0	1
5	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
6	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	2.2	79
7	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	2.2	18
8	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108921.	1.1	10
9	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	2.2	54
10	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , 2020, , 1.	1.3	7
11	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	2.0	182
12	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	2.2	44
13	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
14	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 281-289.	0.9	10
15	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. <i>Diabetic Medicine</i> , 2019, 36, 557-568.	1.2	9
16	Metformin exposure and survival in head and neck cancer: A large population-based cohort study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 588-594.	0.7	13
17	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 361, k1310.	2.4	294
18	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	2.2	71

#	ARTICLE	IF	CITATIONS
19	In type 2 diabetes, weekly semaglutide reduced HbA <sub>1c</sub> and increased weight loss more than weekly exenatide ER. <i>Annals of Internal Medicine</i> , 2018, 168, JC46.	2.0	1
20	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 165.	2.0	38
21	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2017, 98, 563-568.	1.1	10
22	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 843-851.	0.9	19
23	Meta-analysis of artificial pancreas trials: methodological considerations. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 685.	5.5	2
24	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2017, Volume 12, 1-10.	4.7	5
25	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. <i>BMJ Open</i> , 2016, 6, e012185.	0.8	18
26	Most add-on therapies to metformin have similar effects on HbA <sub>1c</sub> . <i>Evidence-Based Medicine</i> , 2016, 21, 223-223.	0.6	0
27	Premixed insulin regimens for type 2 diabetes. <i>Endocrine</i> , 2016, 51, 387-389.	1.1	2
28	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , 2016, 52, 458-480.	1.1	42
29	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 36-38.	1.0	13
30	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	2.2	61
31	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 61-67.	1.4	26
32	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 138-146.	1.0	96
33	Review: Sodium-glucose cotransporter 2 inhibitors reduce HbA <sub>1c</sub> and weight but increase infections. <i>Annals of Internal Medicine</i> , 2014, 160, JC10.	2.0	1
34	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 984-993.	2.2	176
35	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 584-592.	1.5	27
36	Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 262.	2.0	749

#	ARTICLE	IF	CITATIONS
37	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e1369-e1369.	2.4	356
38	Authors' reply to Scheffel and Schaan. <i>BMJ, The</i> , 2012, 344, e2922-e2922.	3.0	1